Indivior PLC (LON:INDV) has agreed a settlement with Mylan Pharmaceuticals Inc (NASDAQ:MYL) to resolve a patent dispute over its heroin addiction treatment, Suboxone sublingual film, around a month after being dealt a blow in another US patent action over the product.
In a statement, the FTSE 250-listed firm said the settlement agreed by its US subsidiary, alongside Monosol Rx LLC, with Mylan Pharmaceuticals Inc, Mylan Technologies Inc, and Mylan NV was on confidential terms.
Indivior filed patent lawsuits against Mylan, among others, earlier this month, for patent infringement of patents related to Suboxone, after a Delaware court issued a ruling at the beginning of September finding that Indian generics firm Dr Reddy's Laboratories Inc had not infringed the UK firm’s patents for the product.
Indivior’s chief executive officer, Shaun Thaxter said today: "The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property.
“Further, as recently demonstrated with our newly granted '454 patent, we expect to expand the intellectual property estate for Suboxone Film and vigorously assert and defend it.”
Indivior saw more than £1bn wiped off its value on September 1 after losing the legal battle to protect its best-selling product from copycat competition.
It launched a legal rearguard action two weeks later, filing patent infringement lawsuits against Dr Reddy's, Actavis, Par, Alvogen, Teva, and Mylan, and said it was ready to appeal the earlier Dr Reddy’s ruling.
Suboxone film is the company’s biggest selling product and responsible for 90% of its revenues.